Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in brain and CNS tumors
- Trial result
Brain and CNS tumors
Lucicebtide/ST101 (C/EBPβ Antagonist) Shows Early Survival Signal in GBM
Lucicebtide (ST101) is a first-in-class peptide antagonist of C/EBPβ designed to suppress the mesenchymal GBM program and reprogram immunosuppressive tumor-associated myeloid cells. In a Phase 2 window-of-opportunity…
NCT04478279 - Trial result
Brain and CNS tumors
GammaTile Cs-131 Brachytherapy + Stupp Cuts Rapid Early Progression to 6% in GBM
GammaTile is a cesium-131 collagen-tile brachytherapy platform implanted at resection to deliver immediate local radiation, then followed by abbreviated EBRT with concurrent/adjuvant temozolomide in the prospective…
NCT05342883 - New trial
Brain and CNS tumors
Phase 1b vorasidenib (dual mutant IDH1/IDH2 inhibitor) plus lomustine alkylator in recurrent IDH-mutant glioma
This Phase 1b, open-label, dose-escalation study (VALIENT) is designed to test whether vorasidenib—a brain-penetrant small-molecule mutant IDH1/IDH2 inhibitor marketed as Voranigo by Servier—can be combined safely…
NCT07629089 Exploratory - New trial
Brain and CNS tumors
Phase 2 cemiplimab PD-1 inhibitor + LITT ablation vs chemo after LITT in rGBM
This randomized Phase 2 study tests whether adding cemiplimab (Regeneron/Sanofi; a PD‑1/CD279–blocking monoclonal antibody that reactivates antitumor T cells) after laser interstitial thermal therapy (LITT;…
NCT07620548 Exploratory - New trial
Brain and CNS tumors
Phase 2 zanzalintinib c-MET/HGFR and VEGFR inhibitor for recurrent/progressive meningioma
This Phase 2, single-arm, multicenter, open-label study evaluates zanzalintinib (Exelixis)—an oral small-molecule tyrosine kinase inhibitor of c-MET/HGFR and VEGFR—aiming to suppress tumor growth signaling and…
NCT07428616 Exploratory - New trial
Brain and CNS tumors
Phase 2 FG001 uPAR-targeted near-infrared fluorescent imaging agent for high-grade glioma surgery.
This prospective, single-group, open-label Phase 2 study tests whether FluoGuide A/S’s FG001 can improve intraoperative visualization of malignant tissue during first surgery for newly diagnosed high-grade glioma.…
NCT07609472 Exploratory - Trial result
Brain and CNS tumors
Preop DSC-MRI perfusion (CBV/CBF) predicts poorer survival in high-grade glioma despite 96% EOR with iMRI
Preoperative MR perfusion (DSC-MRI CBV/CBF) and intraoperative MRI (iMRI) were evaluated in a prospective, single-center pilot cohort of newly diagnosed high-grade glioma (WHO grade 3 astrocytoma + glioblastoma;…
- New trial
Brain and CNS tumors
Phase 1/2 MT-125 non-muscle myosin II (IIA/IIB) inhibitor with chemoradiation in GBM
Myosin Therapeutics’ Phase 1/2 NOVA-GBM study tests MT-125, a CNS-penetrant small-molecule inhibitor of non-muscle myosin II paralogs IIA and IIB, given alongside standard chemoradiation for newly diagnosed…
NCT07604285 Exploratory - Trial result Spotlight
Brain and CNS tumors
ML-guided PPRT (dose-escalated RT boost) doubles PFS in newly diagnosed IDH-wt glioblastoma—at a necrosis cost
Personalized precision radiation therapy (PPRT) is an ML-guided radiotherapy dose-escalation approach that uses MRI-derived “tumor infiltration” maps to boost dose beyond conventional fields; it was prospectively…
NCT03477513 - Trial result
Brain and CNS tumors
GNOS-PV01 personalized neoantigen DNA vaccine drives T-cell expansion and ~16.3-mo mOS in MGMT-unmethylated GBM
GNOS-PV01 is a personalized, multivalent neoantigen DNA therapeutic cancer vaccine (up to 40 neoantigens/patient) given adjuvantly after surgical resection and radiotherapy in the open-label, single-arm Phase 1 GT-20…
NCT04015700 - Trial result
Brain and CNS tumors
MR-Linac adaptive GBM RT shows FLAIR (FHR) omission doesn’t shift failures or survival
UNITED (NCT04726397) is a prospective Phase 2 MR-guided, weekly online-adaptive chemoradiotherapy approach for newly diagnosed glioblastoma using a small GTV-to-CTV margin (CTV=GTV+5mm); clinicians variably extended…
NCT04726397 - New trial Spotlight
Brain and CNS tumors
Phase 1 8R-70CAR (CD70 CAR-T + CXCR2 “IL-8 receptor” trafficking) in brain metastases
This first-in-human Phase 1, single-center, open-label University of Florida study (IMPACT-MET) tests the safety and feasibility of ex vivo–expanded autologous T cells engineered to express a CD70-directed CAR plus…
NCT07569263 First-in-human - New trial Spotlight
Brain and CNS tumors
Phase 1 FT536 MICA/B-directed CAR-NK (MICA/MICB-targeted) for recurrent grade 4 astrocytoma
This single-center, first-in–cancer-type Phase 1, open-label, sequential dose-escalation study tests intratumoral FT536 in adults with recurrent WHO grade 4 astrocytoma (eligible regardless of IDH mutation status)…
NCT07560865 First-in-human - New trial
Brain and CNS tumors
Phase 1 RNA-LP vaccine: CMV pp65–LAMP mRNA + autologous tumor mRNA immunotherapy
This first-in-human Phase 1, open-label, dose-escalation study at the University of Florida tests the manufacturing feasibility, safety, and maximum tolerated dose of an intravenous RNA–lipid particle (RNA-LP) cancer…
NCT07492316 First-in-human - Trial result
Brain and CNS tumors
Bortezomib (26S proteasome/NF-κB inhibition) + sequential temozolomide extends OS to 18.8 months in recurrent uMGMT GBM
Sequential bortezomib (BTZ), an IV 26S proteasome inhibitor that can suppress NF-κB signaling and deplete MGMT protein, was given 48 hours before temozolomide (TMZ) in the BORTEM-17 Phase IB/II recurrent glioblastoma…
NCT03643549 - New trial Spotlight
Brain and CNS tumors
Phase 1 EGFR/IL13Rα2 pool-CAR T cells target EGFR + IL13Rα2 in HGG
City of Hope Medical Center is running a Phase 1, first-in-human, open-label, dose-finding study of autologous “pool-CAR” T cells engineered to recognize EGFR and IL13Rα2 on tumor cells (dual-antigen CAR T…
NCT07544992 First-in-human - New trial
Brain and CNS tumors
Phase 1b sitagliptin DPP-4 inhibitor + bevacizumab anti-VEGF mAb in recurrent grade 4 glioma
This Phase 1 trial tests repurposed sitagliptin (a small-molecule dipeptidyl peptidase-4 [DPP-4] inhibitor; Merck’s Januvia) combined with bevacizumab (a VEGF-A–neutralizing monoclonal antibody; Genentech/Roche’s…
NCT07541781 Exploratory - New trial
Brain and CNS tumors
Phase 1/2 mirdametinib MEK1/2 inhibitor tests MAPK-driven CNS tumors, perioperative glioma cohort
This Phase 1/2, multicenter, open-label Memorial Sloan Kettering (MSK) study evaluates mirdametinib, an oral small-molecule inhibitor of MEK1 and MEK2 in the MAPK pathway, in two biologically selected CNS tumor…
NCT07539441 Exploratory - Trial result
Brain and CNS tumors
Bortezomib (proteasome inhibitor; NF-κB/MGMT suppression) + temozolomide shows 24% RANO responses in recurrent MGMT-unmethylated GBM—biomarker signal tied to HSPBP1 insertion + intact apoptosis/NF-κB
LB014 reports a biomarker-driven readout from the ongoing Phase Ib/II NCT03643549 trial testing sequential bortezomib (a 26S proteasome inhibitor that can blunt NF-κB survival signaling and reduce MGMT) followed by…
NCT03643549 - Trial result
Brain and CNS tumors
Marrow-ablative high-dose chemo (AuHCR) plus re-irradiation links to higher 3-year OS in relapsed CNS NGGCT
A multinational retrospective series of relapsed/refractory central nervous system nongerminomatous germ cell tumors (NGGCT) evaluated marrow-ablative high-dose chemotherapy with autologous hematopoietic stem cell…
- New trial
Brain and CNS tumors
Phase 2 mirdametinib MEK1/2 inhibitor with radiotherapy in NF1-altered high‑grade glioma
University of Alabama at Birmingham (UAB) is running this Phase 2, open-label, parallel, multi-arm study testing mirdametinib—an oral small-molecule MEK1/MEK2 inhibitor (MAPK-pathway blockade downstream of…
NCT07521657 Exploratory - New trial
Brain and CNS tumors
Phase 2 JZP3507 (ONC206) dopamine receptor D2 antagonist small molecule in recurrent high-grade meningioma.
This Phase 2, open-label study sponsored by Jazz Pharmaceuticals evaluates JZP3507 (ONC206), an oral small-molecule dopamine receptor D2 (DRD2) inhibitor, in adults with recurrent/progressive World Health…
NCT07533942 Exploratory - New trial
Brain and CNS tumors
Phase 1 rTMS targets motor-network rebalancing via theta-burst neuromodulation (cTBS/iTBS)
This single-center, open-label pilot study evaluates whether image-guided repetitive transcranial magnetic stimulation (rTMS) can accelerate motor recovery after brain tumor surgery by modulating cortical…
NCT07530536 Exploratory - New trial Spotlight
Brain and CNS tumors
Phase I NSC-CRAd-S-pk7 oncolytic adenovirus ± NAC-amide → then SOC chemoradiation/TTFields
Northwestern assesses repeated intratumoral NSC-CRAd-S-pk7 (± NAC-amide) followed by standard temozolomide-radiation and tumor-treating fields (Novocure) in newly diagnosed grade 3/4 glioma. Despite the Stupp…
NCT06169280 First-in-human - Trial result
Brain and CNS tumors
Abemaciclib (CDK4/6) Hits 68% PFS6 in Recurrent Grade 2/3 Meningioma
Abemaciclib is an oral CDK4/6 inhibitor; in a multicenter basket trial (NCT03220646), an expanded cohort of recurrent meningioma (mostly grade 2–3; n=22) received 200 mg twice daily on 28-day cycles. The meningioma…
NCT03220646 - New trial Spotlight
Brain and CNS tumors
Phase II Trial of LINAC Stereotactic Radiation, Delivering Precise DNA-Damaging Therapy for Brain Metastases
This study evaluates same-day adaptive LINAC-based stereotactic radiation comparing a 0mm versus a 1mm margin in patients with brain metastases from solid tumors. The design randomizes participants to receive…
NCT07132190 Exploratory - Trial result Spotlight
Brain and CNS tumors
Azeliragon (RAGE) + SRS posts 100% 8-wk per-patient RANO response in brain metastases
Azeliragon is an oral, brain-penetrant inhibitor of the receptor for advanced glycation end-products (RAGE) intended to dampen neuroinflammation/edema and potentially radiosensitize tumors; in the single-center Phase…
NCT05789589 - New trial Spotlight
Brain and CNS tumors
Phase 1 CART-EGFR-IL13Rα2 Cells Targeting EGFR and IL13Rα2 in GBM
This open-label study at the University of Pennsylvania examines newly diagnosed glioblastoma patients with EGFR-amplification and MGMT-unmethylation post-radiotherapy. Eligible patients undergo a two-step screening,…
NCT06973096 First-in-human - Trial result Spotlight
Brain and CNS tumors
DOC1021 Autologous DC Vaccine Hits 88% 12-mo OS in IDH-wt GBM (Phase I)
DOC1021 is an autologous dendritic-cell vaccine loaded with each patient’s tumor lysate plus amplified tumor mRNA and injected near deep cervical nodes with weekly peg-IFN after chemoradiation. In a single-arm…
NCT04552886 - New trial Spotlight
Brain and CNS tumors
Phase 1B SONALA-001 Protoporphyrin IX ROS activator with MRgFUS for recurrent glioblastoma
This Phase 1B study, sponsored by Mayo Clinic, evaluates the safety, optimal dosing, and preliminary effectiveness of SONALA-001 (a Protoporphyrin IX ROS activator small molecule) given with MR-guided focused…
NCT07076472 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.